SciBase secures first payer coverage with Highmark, marking a major commercial inflection point

SciBase secures first payer coverage with Highmark, marking a major commercial inflection point

STOCKHOLM, October 14, 2026 /PRNewswire/ --SciBase Holding AB ("SciBase") (STO: SCIB) a leader in advanced technology for the detection and prevention ofskin disease, announced today that Nevisense has received its first positive medical policy from Highmark Blue Cross Blue Shield, one of the largest Blue Cross Blue Shield organizations in the United States.

The decision marks a major milestone in SciBase's U.S. commercialization strategy and changes the reimbursement landscape for Nevisense. For the first time, eligible use of the technology can move from a predominantly cash-pay model into covered care through a major U.S. private insurer, reducing one of the most significant barriers to broader clinical adoption.

SciBase has already established strong commercial momentum in the United States without broad private payer reimbursement. The addition of coverage introduces a new growth driver to an existing business, expanding the number of dermatology practices and patients that can access Nevisense within a reimbursed model.

"This is a defining milestone for SciBase and an important step forward in the development of our U.S. business," said Pia Renaudin, CEO of SciBase. " Highmark coverage begins to remove one of the most important barriers to scale and creates the opportunity to reach a substantially larger portion of the U.S. market. Reimbursement now becomes an additional driver of growth in a business where demand for our technology has already been established."

The United States is SciBase's largest commercial opportunity. Approximately 6,500 to 7,000 private dermatology clinics operate in the U.S., with around 6,000 considered relevant for Nevisense, and an estimated 4 to 4.5 million skin biopsies are performed annually.

The Highmark decision represents more than the addition of a new payer. It begins to address one of the principal constraints on U.S. commercial scale and creates a pathway to convert established clinical adoption into broader reimbursed utilization.

Highmark, together with its Blue-branded affiliates, is one of the largest Blue Cross Blue Shield affiliated organizations in the United States, serving over 7 million members across multiple states.

For dermatologists, reimbursement can reduce the financial barrier to incorporating Nevisense into care for eligible patients while expanding patient access to objective, non-invasive technology that can support the assessment of suspicious skin lesions.

SciBase will continue its engagement across the U.S. payer market while expanding commercial activity in geographies where reimbursement is available.

What the policy covers

Under the policy, Highmark considers EIS medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy.

The procedure is reported with CPT code 0658Tand the key criteria include:

• Melanoma is part of the differential diagnosis
• The lesion is on the trunk or extremities and measures 2 mm to 20 mm
• The patient is 18 or older
• The lesion is not on a mucosal surface, palm, sole or nail, and is not ulcerated, bleeding or recently traumatized
• The device is FDA-approved and used by a dermatologist trained in clinical and dermoscopic evaluation of pigmented lesions
• The policy applies to all Highmark commercial insured lines of business and to self-funded (ASO) employer groups that elect it. In support of its position, Highmark cites the NCCN Clinical Practice Guidelines for Cutaneous Melanoma (Version 2.2026), which list EIS among technologies that may aid detection of new primary melanoma, and American Academy of Dermatology guidance on emerging noninvasive diagnostics.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 09:00 AM CEST on October 14, 2026.

About SciBase  

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more atwww.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-secures-first-payer-coverage-with-highmark--marking-a-major-commercial-inflection-point,c4408544

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/scibase-secures-first-payer-coverage-with-highmark-marking-a-major-commercial-inflection-point-302908213.html

SOURCE SciBase